[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ASST Fatebenefratelli Sacco\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":239},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,76,102,122,157,183,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100615169","peep-titration-guided-by-electrical-impedance-tomography-in-laparoscopic-surgery-the-pearl-study-100615169",false,"NCT07289113","PEEP Titration Guided by Electrical Impedance Tomography in Laparoscopic Surgery The PEaRL Study","Personalized PEEP Titration Guided by Electrical Impedance Tomography in Patients Undergoing Laparoscopic Surgery: A Randomized Controlled Trial - The PEaRL Study","PEaRL","Inclusion Criteria:\n\n* scheduled for laparoscopic abdominal surgery\n* informed consent signed\n\nExclusion Criteria:\n\n* COPD\n* Acute respiratory failure\n* Hemodynamic instability\n* Pregnancy\n* Contraindications for EIT device","ALL","18 Years",{"count":20,"type":21},52,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background:\n\nLaparoscopic surgery has gained widespread adoption due to its minimally invasive nature, offering advantages such as reduced postoperative pain, shorter hospitalization, and faster functional recovery compared with traditional open surgery. Nevertheless, postoperative respiratory complications remain a major source of morbidity. Factors such as general anesthesia, the Trendelenburg position, and CO₂ pneumoperitoneum can impair respiratory mechanics, reduce total lung capacity, and promote atelectasis, leading to compromised gas exchange.\n\nRationale:\n\nPositive end-expiratory pressure (PEEP) is routinely applied to prevent alveolar collapse and improve oxygenation during mechanical ventilation. However, the use of standardized, non-individualized PEEP levels may be suboptimal, as inappropriate settings can cause alveolar overdistension or persistent collapse. Personalized PEEP titration, tailored to patient-specific lung mechanics, has recently emerged as a promising strategy to minimize ventilator-induced lung injury (VILI).\n\nMethods and Tools:\n\nElectrical Impedance Tomography (EIT) is a non-invasive, bedside monitoring technique that enables real-time assessment of regional lung ventilation. By evaluating ventilated and non-ventilated lung areas, EIT can guide PEEP optimization and support individualized ventilatory management. Recent studies suggest that EIT-guided PEEP titration improves respiratory parameters and reduces atelectasis in patients undergoing major surgery.\n\nObjective:\n\nThe present study aims to evaluate the efficacy of EIT-guided PEEP personalization in patients undergoing laparoscopic and robotic surgery. Primary endpoints include improvements in regional ventilation, respiratory system compliance, and intraoperative gas exchange, as well as postoperative pulmonary function.",[27],"Electrical Impedance Tomography",[29,27,30],"PEEP","Laparoscopy","RECRUITING","2026-06-03",{"date":34,"type":35},"2026-06-04","ACTUAL",{"date":37,"type":35},"2026-01-12",{"date":39,"type":21},"2026-11",{"name":41,"class":42},"ASST Fatebenefratelli Sacco","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":43},"100629259","isoniazid-related-hepatotoxicity-in-clinical-practice-incidence-and-predictors-100629259","NCT07472348","Isoniazid-Related Hepatotoxicity in Clinical Practice: Incidence and Predictors","Observational Study on Isoniazid-Induced Hepatotoxicity: Incidence, Risk Factors and Therapeutic Strategies","INH-DILI","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Patients diagnosed with TB or LTBI who received INH as part of their treatment regimen (either first-line or second-line therapy), regardless of combination with other anti-TB drugs.\n* Normal baseline liver function tests (ALT, AST and bilirubin within reference range) and absence of clinical symptoms of liver dysfunction prior to initiation of anti-TB therapy.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients who did not receive isoniazid during their treatment course.\n* Pre-existing liver dysfunction, including biliary origin, before anti-TB therapy.\n* Pregnancy or lactation.\n* Concomitant use of non-TB hepatotoxic drugs.\n* Abnormal hepatic function on baseline laboratory testing.\n* Known INH resistance at treatment initiation.\n* Refusal to provide informed consent.",{"count":53,"type":21},220,"OBSERVATIONAL","The objective of this observational study is to determine how frequently isoniazid (INH) causes liver injury (hepatotoxicity) in adults treated for tuberculosis (TB) or latent tuberculosis infection (LTBI) and to understand which factors increase this risk. The study also aims to describe how hepatotoxicity is managed in real-world clinical practice and whether treatments such as corticosteroids can improve liver function tests.\n\nThe main questions this study aims to answer are:\n\n* How frequently does INH-induced hepatotoxicity occur in adults treated for TB or LTBI?\n* What demographic, clinical, microbiological, or lifestyle factors increase the risk of developing hepatotoxicity?\n* How do different management strategies, including treatment modification or the use of corticosteroids, affect liver recovery and completion of TB\u002FLTBI therapy? This study does not involve experimental treatments. Researchers will analyze information already collected during routine clinical care, both retrospectively (from 2020 to 2025) and prospectively (2026-2028). There is no comparison group, but participants may have different clinical profiles or treatments, which will be compared to understand risk factors and outcomes.\n\nParticipants will:\n\n* Receive standard treatment for tuberculosis or LTBI, including isoniazid, as prescribed by their treating physicians.\n* Undergo routine assessments, such as blood tests, microbiology, imaging, and clinic visits, as part of their regular care.\n* Their clinical data will be recorded in the study database to analyze liver function trends, treatment changes, and outcomes.\n\nThe study will contribute to improving understanding of INH-induced hepatotoxicity and supporting safer and more effective treatment strategies for tuberculosis and LTBI.",[57,58],"Tuberculosis Infection","Tuberculosis Infection, Latent",[60,61,62,63,64,65,66],"Isoniazid","INH-induced hepatotoxicity","Drug-induced liver injury","Tuberculosis","Corticosteroid therapy","Observational study","Adverse drug reactions","NOT_YET_RECRUITING","2026-03-10",{"date":70,"type":35},"2026-03-16",{"date":72,"type":21},"2026-05-30",{"date":74,"type":21},"2026-09-01",{"name":41,"class":42},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":43},"100595512","a-trial-of-approach-bias-modification-training-during-treatment-for-cocaine-use-disorder-100595512","NCT07033416","A Trial Of Approach Bias Modification Training During Treatment For Cocaine Use Disorder","A Pilot Randomised Controlled Trial of Approach Bias Modification During Traetment for Cocaine Use Disorder","ABMCocaine","Inclusion Criteria:\n\n* participants must be aged at least 18 years;\n* current DSM 5 TR Cocaine Use Disorder;\n* sufficient Italian language proficiency to understand the participant information sheet, questionnaires and intervention task instructions;\n* signed Consent form.\n\nExclusion Criteria:\n\nParticipants are excluded from participating if they have:\n\n* neurological disorder or injury or brain trauma involving loss of consciousness for longer than 30 minutes;\n* severe psychiatric disorder, as evaluated by clinical judgement;\n* antipsychotic medication;\n* intellectual disability;\n* missing Informed Consent;\n* planned absence from attendance through the training period (one month).",{"count":85,"type":21},60,[24],"The goal of this clinical trial is to investigate if the intervention \"Approach Bias Modification\" (ABM) can low cocaine craving in people with Cocaine Use Disorder (CUD).\n\nThe main question this clinical trial aims to answer is how many days participants can be in abstinence from cocaine after 4 ABM sessions.\n\nABM is a computerised training aiming to train the participants to:\n\n* avoid drug-related images by pushing a joystick which causes the image to disappear;\n* approach positive images by pulling a joystick which causes the image to expand.\n\nResearchers will compare participants treated with ABM to those who receive Treatment As Usual (TAU) condition to see if ABM training for CUD is more effective in increasing the number of abstinent days.\n\n* Participants will attend 1 ABM session per week for a total of 4 sessions, each lasting 15 minutes.\n* Both cocaine and non-cocaine positive images relative to the subjective values or interests (i.e. effects, sport, music, nature, work, etc.) are presented to the participant, in portrait or landscape orientation.\n* Participants are instructed to push the joystick if the image is portrait-oriented (cocaine-related images) or to pull the joystick if it is landscape-oriented (positive images).\n* At 1 and 3-month-follow up, participants will complete self-report questionnaires to measure abstinence days and describe the effect of ABM on cocaine use, dependence symptoms, and approach bias.",[89],"Training for Cocaine Use Disorder",[91,92,93],"APPROACH BIAS MODIFICATION","RCT","COCAINE USE DISORDER","2025-12-23",{"date":96,"type":35},"2025-12-24",{"date":98,"type":21},"2026-03-31",{"date":100,"type":21},"2026-10-31",{"name":41,"class":42},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":43},"100544119","entities-and-variables-related-to-catch-up-growth-100544119","NCT06364735","Entities and Variables Related to Catch-up Growth","Entities and Variables Related to Catch-up Growth in Pediatric Patients With Celiac Disease (CD) on a Gluten-free Diet (GFD)","Inclusion Criteria:\n\n* celiac disease diagnosis established at the V. Buzzi Children\\'s Hospital in Milan between January 2010 and December 2020, excluding the extremes, in accordance with the ESPGHAN 2012 or 2020 recommendations.\n\nExclusion Criteria:\n\n* patients with unclear or non-specific duodenal histological alterations (e.g., atrophy with unavailable or negative specific antibodies for celiac disease);\n* patients with additional chronic illnesses;\n* absence of the data required for the study;\n* patients with IgA deficiency, defined as IgA \\<20 mg\u002Fdl in children \\<3 years old or with levels that are below normal for their age.",{"count":110,"type":21},900,"A retrospective monocentric observational no-profit study with the aim of evaluating the entity and potential variables influencing the catch-up growth of childhood gluten-free diet patients with celiac disease during a 10-year follow-up. The only extrapolation of the data collected in anonymized form from the medical records of patients who match the necessary study criteria will be planned in order to achieve this aim. A 900-patient sample size will be planned.",[113],"Celiac Disease in Children","2024-08-15",{"date":116,"type":35},"2024-08-19",{"date":118,"type":35},"2024-07-01",{"date":120,"type":21},"2025-01-01",{"name":41,"class":42},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":131,"conditions":132,"keywords":142,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":43},"100554564","visual-involvement-in-giant-cell-arteritis-100554564","NCT06500728","Visual Involvement in Giant Cell Arteritis","Visu-GCA","Inclusion Criteria:\n\n* For GCA group:\n\n  * Patients older than 18 years with clinically suspected or confirmed gigantocellular arteritis.\n  * Newly found visual involvement with suspected or confirmed correlation with vasculitis.\n  * Ability to express valid consent to study enrolment.\n* For control group:\n\n  * Patients older than 18 years with the ability to express valid consent to study enrolment.\n  * Newly diagnosed acute visual impairment with GCA phenotypes (e.g. AION, CRAO) but without any correlation with vasculitis aetiology.\n\nExclusion Criteria:\n\n* Pre-existing ophthalmological pathologies that may modify best visual acuity and\u002For alter ophthalmological semeiotics.\n* Concomitant active viral, bacterial, fungal and parasitic infections, including active or latent tuberculosis treated for less than 4 weeks and HIV, hepatitis C virus (HCV)\n\n  \u002Fhepatitis B virus (HBV) infections, involving the eyes and orbital cavities.\n* Concomitant systemic inflammations not attributable to GCA (inflammatory diseases in treatment-free remission are not excluded).\n* Any other condition judged by the investigators to be a contraindication of eligibility",{"count":130,"type":21},762,"This observational study aims to enhance the description of the different ways Giant Cell Arteritis (GCA) affects vision. The latest technology and knowledge are used to improve how we diagnose and predict patient outcomes. GCA is the most frequent vasculitis, an inflammation of vessels, in older adults. It involves large and medium-sized arteries and causes ischemic alterations such as stroke and blindness, through damage of extracranial arteries.\n\nThe primary objective is to compare the frequency of the various ocular findings between the main alterations of arteritic and non-arteritic aetiology, such as Arteritic Anterior Ischemic Optic Neuropathy (A-AION) Vs. Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) or Central Retinal Artery Occlusion (CRAO) from GCA Vs. from other causes, through a comprehensive clinical and instrumental evaluation.",[133,134,135,136,137,138,139,140,141],"Giant Cell Arteritis","Visual Impairment","Central Retinal Artery Occlusion","Anterior Ischemic Optic Neuropathy","Paracentral Acute Middle Maculopathy","Posterior Ischemic Optic Neuropathy","Retinal Ischemia","Blindness","Visual Disorder",[133,143,144,145,146,147,148],"Visual impairment","Optical Coherence Tomography (OCT)","High resolution Optical Coherence Tomography (HR-OCT)","Angio-Optical Coherence Tomography (OCT-A)","Fluorescein angiography","Indocyanine green angiography","2024-07-08",{"date":151,"type":35},"2024-07-15",{"date":153,"type":35},"2024-06-27",{"date":155,"type":21},"2030-06",{"name":41,"class":42},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":182},"100510388","clinical-phenotypes-in-pericarditis-il-1ra-antibodies-and-supar-levels-100510388","NCT05925790","Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels","Observational Study on Anti-interleukin-1 Receptor Antagonist Antibodies and Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Pericarditis: PERIPLO (PERicarditis: IL-1 RA Antibodies and suPAR Levels Observational) Study","PERIPLO","Inclusion Criteria:\n\n* Written informed consent from patients aged ≥ 18 years before any evaluation is performed.\n* Written informed consent from parents or legal guardian and assent from minors aged under 18 years before any evaluation is performed.\n* Recurrent acute pericarditis during the acute phase of the disease. The diagnosis of pericarditis is based on the presence of at least two of the following criteria: typical pericarditic chest pain (acute and pleuritic, worsened by positional changes or breathing), pericardial friction rub, diffuse ST segment elevation or PR depressions not previously reported, and pericardial effusion.\n* Post-cardiac injury pericarditis (e.g., post-cardiac surgery) that is new or worsening. Recurrence is diagnosed based on the same criteria.\n\nIn all patients, the previous history of CRP values should be known to distinguish individuals with inflammatory forms (characterized by significantly elevated CRP values in the clinical history) from those with pericarditis and normal or near-normal CRP levels (clinical history of normal or at most less than 2 times the normal value).\n\nThe acute phase of the disease is defined as follows: for pericarditis forms with elevated CRP, the presence of a CRP that is at least double the normal value of the test. For forms with normal CRP, it is based on clinical judgment, as there are no other recognized and validated criteria.\n\nExclusion Criteria:\n\n* Specific etiologies, including tuberculosis, neoplastic or purulent etiologies, post-cardiac injury syndromes, and autoimmune rheumatic diseases.\n* Subjects under 18 years of age.\n* Pregnant or lactating women.\n* History of immunosuppression, including a positive result on HIV screening tests (ELISA and Western blot).\n* Positive QuantiFERON test (QFT-Tuberculosis G In-Tube) or positive Purified Protein Derivative (PPD) test after the initial clinical evaluation.\n* History of other significant medical conditions that, according to the investigator, could compromise the outcome or interpretation of the results (e.g., systemic diseases that are not directly the cause of pericarditis but may cause a state of chronic inflammation).\n* Use of any medication that the investigator believes could alter the result of the tests to be performed (except those used for the treatment of pericarditis).\n\nThroughout the study, patients will continue to receive the most appropriate therapies for their clinical condition, following current guidelines and good clinical practice, without the participation in the study prejudicing or influencing the choice of therapeutic strategies to be employed.","90 Years",{"count":167,"type":21},146,"This study aims to investigate the pathophysiology of recurrent pericarditis (RP) by testing for neutralizing autoantibodies against interleukin-1 receptor antagonist (IL-1RA) and measuring soluble urokinase plasminogen activator receptor (suPAR) levels. The hypothesis is that these tests will provide insights into both the inflammatory and non-inflammatory phenotypes of RP, shedding light on the underlying mechanisms. The study will assess the correlation between antibody levels, suPAR levels, and markers of cardiac damage and inflammation. Longitudinal testing during acute episodes and intercritical phases is also planned. The results may guide the use of anakinra, an IL-1 receptor antagonist, in specific clinical scenarios and optimize treatment strategies for RP.",[170],"Pericarditis",[170,172,173,174],"Anti-interleukin-1 receptor antagonist antibodies","Soluble urokinase plasminogen activator receptor","Pericarditis phenotypes",{"date":176,"type":35},"2024-07-03",{"date":178,"type":35},"2023-07-01",{"date":180,"type":21},"2025-12-20",{"name":41,"class":42},9,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":190,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100546677","phase-4-a-study-to-investigate-the-analgesic-efficacy-of-ibuprofen-alone-and-ibuprofen-plus-hyoscine-n--butyl-bromide-in-reducing-pain-of-outpatient-hysteroscopy-100546677","NCT06398054","A Study to Investigate the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducing Pain of Outpatient Hysteroscopy","Comparison of the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducing Pain of Outpatient Hysteroscopy: a Randomized, Phase iv, Double-blind Trial","Inclusion Criteria:\n\n* female patients older than 18 years who signed informed consent;\n* patients who need an office hysteroscopy for their diagnosis or treatment. Those indications included postmenopausal endometrial thickening (over 4 mm), metrorrhagia, sonographic suspicion of endometrial polyps or myomas, Essure device insertion, and endometrial biopsy\n\nExclusion Criteria:\n\n* women with a possible pregnancy, ongoing vaginal bleeding, lower genital tract infection, gestational trophoblastic disease, asthma, hepatitis, renal failure, lactation, previous cervical surgery, or oversensitivity to one of the agents or their elements;\n* patients suffering from neuropathic pain or other conditions that can impact on the perception of pain;\n* individuals who use antidepressant, anxiolytics or other drugs\u002Fsupplements that may have an impact on the perception of pain;\n* contraindications to the use of ibuprofen and\u002For Hyoscine N-Butil Bromide .","FEMALE",{"count":192,"type":21},190,[194],"PHASE4","For outpatient hysteroscopy (OH), it is recommended to take a standard dose of NSAIDs or more hyoscine-n butyl bromide (HBB) an hour prior to the procedure to minimize pain during the first postoperative hour. As there is currently no clear consensus in the literature regarding the best approach to pain management associated with office hysteroscopy procedures. This Phase 4 study is being conducted to evaluate the effectiveness of oral ibuprofen alone and in combination with HBB to determine the most appropriate strategy for improving pain perception in outpatients.",[197],"Pain",[199],"hysteroscopy","2024-05-08",{"date":202,"type":35},"2024-05-10",{"date":204,"type":21},"2024-10-01",{"date":206,"type":21},"2026-10-01",{"name":41,"class":42},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":215,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":218,"conditions":219,"keywords":224,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":4},"100534841","clonal-hematopoiesis-in-giant-cell-arteritis-100534841","NCT06244069","Clonal Hematopoiesis in Giant Cell Arteritis","CH-GCA","Inclusion Criteria:\n\n* Patients with suspected active GCA entering into a fast-track work-up and healthy matched controls.\n* Capability of providing valid consent to study enrollment.\n* Possibility of performing temporal artery biopsy within three hours from enrollment.\n\nExclusion Criteria:\n\n* Active concurrent viral, fungal or bacterial infections (including active\u002Flatent tuberculosis treated for less than 4 weeks, HIV and Hepatitis B\u002FC virus (HBV\u002FHCV) infections.\n* Concurrent systemic inflammation not attributable to GCA (inflammatory diseases in treatment-free remission are accepted).\n* Use of other immunosuppressive agents in the last 3 months.\n* Use of systemic steroids (any dose in the last week, \\> 15 mg\u002Fdie of prednisone equivalent in the last month).\n* Solid or hematologic malignancies (active or with less than 6 months free of disease or antiblastic chemotherapy (hormone therapy is allowed).\n* Previous solid or hematopoietic stem cell transplantation (corneal transplants are allowed).\n* Any systemic immunosuppressive or steroidal therapy.\n* Chronic renal failure with Glomerular Filtration Rate (GFR) \\\u003C 45 ml\u002Fmin \\*1.73 m2.\n* Moderate-severe liver failure (Child-Pugh B or C), hepatitis in stages of activity.\n* Diabetes mellitus.\n* Heart failure with New York Heart Association score (NYHA) \\>=2.\n* Severe hypoproteinemia\u002Fmalnutrition.\n* Chronic respiratory failure requiring O2 therapy or ventilation therapy at home.\n* Any other condition judged by the local investigator as a contra-indication to eligibility.",true,{"count":217,"type":21},326,"The goal of this clinical trial is to verify whether CHIP is correlated with the clinical, instrumental, and histological characteristics of GCA, and to characterize the pathogenetic effects of clonal hemopoiesis on vasculitis. The main objective of this study is to verify if clonal hematopoiesis of indeterminate potential (CHIP) affects GCA manifestations, course\u002Fresponse to therapies, and pathogenesis.\n\nPatients who are going to be diagnosed with GCA and for which a fast track is available for a rapid diagnostic work-up including pre-treatment temporal artery biopsy. Patients with CHIP will be identified and characterized by using whole exome sequencing from the peripheral blood samples. The presence and characteristics of CHIP will be correlated with baseline clinical, instrumental, and histologic GCA features.",[133,220,221,222,223],"Temporal Arteritis","Clonal Hematopoiesis of Indeterminate Potential","Horton Disease","Systemic Vasculitis Primary",[225,226,221,227,228,229,230],"Temporal artery biopsy","Giant cell arteritis","Single cell transcriptomics","Large vessels vasculitis","Horton disease","Whole Exome Sequencing","2024-02-02",{"date":233,"type":35},"2024-02-06",{"date":235,"type":21},"2024-03",{"date":237,"type":21},"2031-03",{"name":41,"class":42},""]